All In Biotech

Drug Trial Radar · NCT02520362

Denosumab Safety Assessment in Multiple Observational Databases

Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis (PMO), Men With Osteoporosis, and Men and Women Who Receive Prolia With Glucocorticoid Exposure in Multiple Observational Databases

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

517,991

Actual

Start

May 31, 2010

Primary completion

Jul 21, 2023

Study completion Jul 21, 2023

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Aarhus University Hospital; Optum, Inc.; University of Alabama at Birmingham
First posted
Aug 11, 2015

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 30 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective open-cohort study with annual assessment and reporting of descriptive findings from 5 secondary data sources, US Medicare, Optum Research Database (formerly United HealthCare), Scandinavian national health registry databases, including data from Denmark, Sweden, and Norway. The study period will include up to 10 years in each data system depending on data availability. Descriptive statistics will be used to characterize cohorts with respect to patient characteristics and utilization patterns. Person-year adjusted AESI incidence rates will be calculated among postmenopausal women, postmenopausal women with osteoporosis, and exposure cohorts with a final comparative safety analysis. Subsequent sub-studies using US data systems were added to describe men with osteoporosis treated with Prolia and men and women who receive Prolia with glucocorticoid exposure.

Conditions

  • Osteoporosis

Interventions

  • denosumabDrug

    subcutaneous injection

  • bisphosphonateDrug

    The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rates of Adverse Events of Special Interest (AESI)Time frame: Up to 10 years
  2. Characteristics and Adverse Events of Special Interest (AESI) risk factorsTime frame: Up to 10 years
  3. Compare the incidence of the Adverse Events of Special InterestsTime frame: Up to 10 years
  4. Describe incidence rates of Adverse Events of Special Interest (AESI)Time frame: Up to 10 years
  5. Describe denosumab utilization patternsTime frame: Up to 10 years
  6. Describe Prolia utilization patternsTime frame: Up to 10 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.